MetaVia

MetaVia (NASDAQ: $MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, including #obesity and #MASH.

[MetaVia @MetaViaTx]

Hyung Heon Kim, CEO and Marshall H. Woodworth, CFO, will present an update highlighting the company’s pipeline of novel obesity and metabolic therapies at @EmergingGrowthC on Thursday, June 11, 2026 at 3:25 pm ET. For registration, please visit: https://t.co/66y4dW8gjU $MTVA

[MetaVia @MetaViaTx]

GLP-1s revolutionized obesity treatment, but efficacy alone isn’t enough if patients can’t stay on their treatment. MetaVia CEO HH Kim breaks down why patient experience, simpler dosing, and faster titration are now central to obesity drug development. https://t.co/BHyFOuBo5u $MTVA

[MetaVia @MetaViaTx]

What happens when GLP-1s work too well? MetaVia CEO Hyung Heon Kim explores the future of metabolic disease, from precision pathway targeting to long-term maintenance strategies, and discusses the next phase of the GLP-1 era. Read more: https://t.co/5DDgvsOrh3 $MTVA

[MetaVia @MetaViaTx]

Exploratory FibroScan assessments from our Ph. 1 study of DA-1726 demonstrated early liver-related improvements, while the 48 mg cohort achieved up to 9.1% mean body weight reduction at Day 54 with no evidence of plateau. Read more: https://t.co/pcYQ9f2GTP #EASL2026 $MTVA

[MetaVia @MetaViaTx]

Hyung Heon Kim, CEO of MetaVia, comments on the presentation of higher-dose Phase 1 results for DA-1726 at the European Association for the Study of the Liver Congress 2026, being held May 27-30 in Barcelona, Spain: https://t.co/pcYQ9f2GTP #EASL2026 $MTVA

[MetaVia @MetaViaTx]

MetaVia announced new Ph.1 data supporting potential of DA-1726 in obesity and MASH, featured in a late-breaking poster presentation at #EASL2026. Ongoing Ph.1 Part 3a/3b titration studies continue to evaluate extended treatment at higher-dose levels. https://t.co/atcXfNMTUg $MTVA

[MetaVia @MetaViaTx]

Hyung Heon Kim, President and CEO of MetaVia, comments on the recent publication of new preclinical research supporting the anti-fibrotic potential of vanoglipel in MASH. Read more: https://t.co/att589m4iG $MTVA

[MetaVia @MetaViaTx]

MetaVia today announced the publication of new preclinical research supporting the anti-fibrotic potential of vanoglipel (DA-1241), a novel GPR119 agonist, in the peer-reviewed, international journal, Biomolecules & Therapeutics. Read more: https://t.co/att589m4iG $MTVA

[MetaVia @MetaViaTx]

“Having three late-breaking abstracts accepted for poster presentations at the prestigious ADA conference is a testament to the strength of our cardiometabolic portfolio,” said Hyung Heon Kim, President and CEO. More on the upcoming presentations: https://t.co/hwzMyd1QH9 $MTVA

[MetaVia @MetaViaTx]

MetaVia announced that three late-breaking abstracts on its cardiometabolic assets, DA-1726 (GLP-1/glucagon dual agonist) and vanoglipel (GPR119 agonist), were accepted for poster presentations at the ADA 2026 Scientific Sessions, June 5-8, 2026 in NOLA. https://t.co/xvpyUpTW0N $MTVA

[MetaVia @MetaViaTx]

Hyung Heon Kim, Chief Executive Officer of MetaVia, comments on the Company's clinical progress in first quarter of 2026. Read more: https://t.co/opAUy96Isb $MTVA

[MetaVia @MetaViaTx]

MetaVia today announced financial results for the first quarter ended March 31, 2026, and provided a corporate strategic update. For key business updates and upcoming milestones, visit: https://t.co/CD106qFybo $MTVA

[MetaVia @MetaViaTx]

"Having a late-breaking abstract on DA-1726 accepted for a poster presentation at the prestigious EASL Congress underscores the strength of this asset," said Hyung Heon Kim, President and CEO of MetaVia. More on the upcoming #EASLCongress presentation: https://t.co/YxM55QfkeQ $MTVA

[MetaVia @MetaViaTx]

MetaVia announced that a late-breaking abstract on DA-1726, a novel dual OXM analog targeting GLP-1 and GCGR receptors for treatment of obesity, was accepted for a poster presentation at the #EASLCongress 2026, taking place May 27–30 in Spain. https://t.co/yegUoBDXj1 $MTVA

[MetaVia @MetaViaTx]

MetaVia CEO H.H. Kim joined @BioBossPodcast to discuss his path to biopharma leadership and the potential of MetaVia's clinical pipeline across obesity, MASH, and glycemic control. Listen to the full podcast episode here: https://t.co/docOGEYPL5 $MTVA

[MetaVia @MetaViaTx]

The 16-week study of our novel dual OXM analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors evaluates one-step dose titration to 48 mg and two-step dose titration to 64 mg in obese otherwise healthy adults. Read more: https://t.co/oN1oW1MRcu $MTVA

[MetaVia @MetaViaTx]

“Dosing the first patient in these higher-dose cohorts is an exciting milestone that moves us closer to unlocking the full potential of DA-1726,” said Hyung Heon Kim, President and MetaVia CEO. Read more on the higher-dose Phase 1 study of DA-1726: https://t.co/oN1oW1MRcu $MTVA

[MetaVia @MetaViaTx]

MetaVia today announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Read more: https://t.co/oN1oW1MRcu $MTVA

[MetaVia @MetaViaTx]

Hyung Heon Kim, CEO of MetaVia, recaps the Company's FY 2025 cardiometabolic progress, including Ph. 1 results for lead asset DA-1726 showing 9.1% weight loss, improved glucose control and direct liver benefit, and previews path forward into 2026: https://t.co/zMzZcVAoGx $MTVA

[MetaVia @MetaViaTx]

Metavia today announced financial results for the year ended December 31, 2025, and provided a corporate strategic update. Read more: https://t.co/zMzZcVAoGx $MTVA